Phase III Trial Initiated for BLP25 Liposome Vaccine in Breast Cancer Patients

Publication
Article
OncologyONCOLOGY Vol 23 No 8
Volume 23
Issue 8

Merck KGaA of Darmstadt, Germany, has initiated a global phase III trial of BLP25 liposome vaccine (L-BLP25, Stimuvax) in patients with hormone receptor–positive, locally advanced, recurrent or metastatic breast cancer.

Merck KGaA of Darmstadt, Germany, has initiated a global phase III trial of BLP25 liposome vaccine (L-BLP25, Stimuvax) in patients with hormone receptor–positive, locally advanced, recurrent or metastatic breast cancer. L-BLP25 is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.

The phase III placebo-controlled trial, named STRIDE (STimulating immune Response In aDvanced brEast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries. The primary endpoint of STRIDE is progressionfree survival. Overall survival, quality of life, tumor response, and safety will also be assessed.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content